Waters Corporation (WAT) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended July 2, 2005, and the six-month period ended on the same date. Waters Corporation designs, manufactures, and services analytical instrument systems, including liquid chromatography (LC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: Waters Division and TA Instruments Division.
Key Financial Metrics
| Metric | Three Months Ended July 2, 2005 | Six Months Ended July 2, 2005 |
|---|---|---|
| Total Net Sales | $284.6 million | $552.9 million |
| Gross Profit | $167.6 million (58.9% margin) | $324.1 million (58.6% margin) |
| Operating Income | $67.0 million | $124.8 million |
| Net Income | $54.1 million | $100.7 million |
| Diluted EPS | $0.46 | $0.84 |
| Cash and Equivalents | $615.2 million (Balance Sheet) | N/A |
| Operating Cash Flow | N/A | $163.1 million |
| Total Debt | $657.4 million (Current + Long-term) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 9% for the quarter and 7% for the six-month period compared to the prior year. Growth was driven by LC, MS, and TA product lines, with currency translation contributing approximately 1%.
- Operating Income: Reported operating income decreased $11.9 million for the quarter and $4.9 million for the six-month period. This decline is primarily due to the absence of a $17.1 million litigation gain recorded in the prior year's second quarter (Perkin-Elmer settlement). Excluding this one-time gain, operating income actually increased.
- Interest Expense: Interest expense rose significantly ($3.9 million for the quarter) due to increased borrowings under the credit facility to fund the share repurchase program.
- Effective Tax Rate: The effective tax rate decreased to 18.7% for the quarter (from 25.2% in the prior year) and 19.3% for the six-month period (from 23.2%), largely due to a higher mix of income in international jurisdictions with lower tax rates.
Guidance, Outlook, and Risks
- Outlook: Management expects European business to continue improving after a weak first quarter caused by delayed capital budgets from pharmaceutical customers. Industrial spending is anticipated to remain strong. Selling and administrative expenses are expected to grow at or slightly above the rate of sales growth for the full year.
- Share Repurchases: The company continues its $500 million share repurchase program. As of July 2, 2005, $304.9 million had been utilized to repurchase 6.8 million shares.
- Repatriation of Earnings: The Board approved the repatriation of $500 million in foreign earnings under the American Jobs Creation Act (AJCA). A tax liability of approximately $22.0 million to $28.0 million is expected to be recorded in the third quarter of 2005.
- Accounting Changes: The adoption of SFAS 123(R) regarding share-based payments will have a material impact on results of operations starting in fiscal year 2006.
- Litigation: Ongoing patent litigation with Hewlett-Packard (Agilent) remains a contingency. While the company won a non-infringement ruling in the UK and Germany, appeals and new actions are pending. A provision of $3.0 million remains on the balance sheet.
Investor Verification Checklist
- Debt Levels: Verify the impact of the increased debt load ($657.4 million total) on future interest expenses and liquidity.
- Pharmaceutical Spending: Monitor the recovery of European pharmaceutical capital budgets, which previously caused delays in orders.
- Repatriation Tax Impact: Confirm the exact tax liability recorded in Q3 2005 related to the $500 million dividend repatriation.
- Stock-Based Compensation: Assess the magnitude of the expense impact from the upcoming adoption of SFAS 123(R) in 2006.
- Litigation Resolution: Track the status of the Hewlett-Packard/Agilent patent disputes, particularly the rescheduled damages trial in the UK.